What are you talking about?
From the first page of the last quarterly- “Ptx 100 and 200 clinical trials both recruiting to schedule
with no safety issues”.
We knew it would be delayed early last year because they changed the administration schedule of the drug and COVID-19 running rampant in the US.
The good news is we have 3CR’s in what the trial administrator termed a very difficult to treat patient
group with few treatment options.
If you lack patience don’t invest in biotechs.
PTX100, Professor H.Miles Prince, Car-T and OmniCAR, page-35
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
